Correspondence: PDF OnlySafety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia a multicenter survey in ChinaYang, Yunfan1; Zhang, Yanli2; Jiang, Qian3; Meng, Li4; Li, Weiming5; Liu, Bingcheng6; Liu, Xiaoli7; Zhou, Li8; Liang, Rong9; Zhu, Xiaojian4; Xu, Na7; Kuang, Pu1; Lin, Ting1; Zhu, Huanling1Editor(s): Lyu, Peng Author Information 1Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China 2Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Tumor Hospital, Zhengzhou, Henan 450000, China 3Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100000, China 4Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China 5Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China 6Department of Leukemia, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China 7Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510000, China 8Department of Leukemia, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201100, China 9Department of Hematology, Xijing Hospital, Air Force Medical University of PLA, Xi’an, Shaanxi 710000, China. Correspondence to: Dr. Huanling Zhu, Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Guoxuexiang 37, Chengdu, Sichuan 610041, China E-Mail: [email protected] How to cite this article: Yang Y, Zhang Y, Jiang Q, Meng L, Li W, Liu B, Liu X, Zhou L, Liang R, Zhu X, Xu N, Kuang P, Lin T, Zhu H. Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicenter survey in China. Chin Med J 2021;00:00–00. doi: 10.1097/CM9.0000000000001899 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.cmj.org). Received July 5, 2021 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 Chinese Medical Journal: December 29, 2021 - Volume - Issue - doi: 10.1097/CM9.0000000000001899 Open SDC PAP Metrics © 2022 by Lippincott Williams & Wilkins, Inc.